Shares of DexCom have moved -2.2% today, and are now trading at a price of $104.61. In contrast, the S&P 500 index saw a 1.0% change. Today's trading volume is 2,678,195 compared to the stock's average volume of 3,080,346.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. Based in San Diego, United States the company has 7,500 full time employees and a market cap of $40,575,291,392.
The company is now trading -29.97% away from its average analyst target price of $149.37 per share. The 19 analysts following the stock have set target prices ranging from $130.0 to $175.0, and on average give DexCom a rating of buy.
Over the last 52 weeks, DXCM stock has risen 22.0%, which amounts to a 14.0% difference compared to the S&P 500. The stock's 52 week high is $139.55 whereas its 52 week low is $78.94 per share. Based on DexCom's average net margin growth of 17.8% over the last 6 years, its core business is on track for profitability and its strong stock performance may continue in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-09 | 2,909,800 | 341,200 | 12 | 33.33 |
| 2022-02-14 | 2,448,500 | 216,900 | 9 | -67.86 |
| 2021-02-11 | 1,926,700 | 549,700 | 28 | 300.0 |
| 2020-02-13 | 1,476,000 | 101,100 | 7 | 158.33 |
| 2019-02-21 | 1,031,600 | -127,100 | -12 | -71.43 |
| 2018-02-27 | 718,500 | -50,200 | -7 |
